India Aneurysm Coiling and Embolization Devices Market Size Share 2022-2029

Increasing Frequency of Unruptured Intracranial Aneurysm (Uias) 

The rising frequency of unruptured intracranial aneurysm (UlAs) detection is one of the major factors driving the aneurysm coiling and embolization devices market growth. The surveillance for UIAs is a recent phenomenon. In 9% of the brain, one or more unruptured aneurysm had been found when looked for, on routine postmortem examination in the elderly. With the large-scale use of imaging methods, more and more UIAs are now being detected. It is now accepted that just more than 3% of the population harbors an UIA in their brain.  More physicians are focusing on improving the detection rate of UlAs to prevent future rupture. This is leading companies to innovate advanced techniques to identify aneurysms such as IAs associated with arteriovenous malformations that were previously difficult to distinguish from surrounding vessels. The detection rate of UIAs is improving with technological advances in digital subtraction angiography, MRA, and CTA. Electrocardiogram-gated 4DCTA have specific features to detect aneurysm pulsations with the cardiac cycle.  The increasing number of UIA detectors in advanced CT offers better contrast bolus timing, higher resolution, and thinner collimation. This improves the detection of UIAs using aneurysm coiling and embolization devices.  Thus, the increasing frequency of unruptured intracranial aneurysm (UIAs) detection is expected to boost the growth of the market over the forecast period.

Technological Advancement In Aneurysm Coiling And Embolization Devices

The manufacturers are introducing advanced detectors that can detect variations in aneurysm wall thickness, which may be a marker of rupture risk.  Such improvements are encouraging surgeons to perform neuro endovascular coiling and stenting procedures using aneurysm coiling and embolization devices, boosting the market growth. Several organizations, research centers, and vendors are introducing new aneurysm coiling and embolization devices by increasing R&D investments. They are introducing advanced devices that drive the growth of the market in India.

For instance,In March 2020, the research team of Sree Chitra Thirunal Institute of Medical Science and Technology (SCTIMST), developed aneurysm clips for the treatment of aneurysm of the blood vessels of the brain. The surgical treatment of an aneurysm involves opening the skull and a clip on the neck of the aneurysm, so that it is cut off from the path of blood flow. In June 2019, two patients at the BMC-run KEM Hospital were the first in the country to receive the WEB device to treat aneurysms, which has only recently been approved for use in India.  Top neuro interventionist Dr Jacques Moret, professor of Interventional Neuroradiology, NEURI center, France performed the surgeries, which were relayed live to 300 other neuro interventionists.

Market Opportunities

Technological advancements have expanded the role of aneurysm coiling and embolization technological devices to play a key role at all stages of the healthcare chain – increasing access, screening, diagnosis, treatment, preparation and monitoring. With the rapid introduction and adoption of the newer aneurysm coiling and embolization devices, the Indian coil market is expected to grow at a rapidly combined average growth rate over the forecast period. India is one of the hotbeds for startups offering huge opportunities. This is reflected in the Global Startup Ecosystem Ranking where Bangalore was placed #15 on the list. Delhi and Mumbai, two other India cities, were also featured in the top 20. The rapidly expanding neurological devices sector presents immense opportunities to manufacturers of aneurysm coiling and embolization devices. The Indian interventional neurological market is fast evolving and vibrant with academic research, venture capital firms, government funding and promising startups developing products specifically for the Indian market.  In India, as part of these newly introduced regulations, device registration fees have been reduced to facilitate the availability of high-end medical devices in the country. Furthermore, these regulations include a shift from four to two-phase clinical trials, making it easier for manufacturers to increase their footprint in the market. From January 2018, the newly drafted regulations have been implemented in accordance with the Global Harmonization Task Force (GHTF) framework, resulting in the adoption of global best practices.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com